Reports preliminary FY25 gross revenue EUR 11M. “Our first full quarter of U.S. commercialization post-FDA approval resulted in strong momentum,” commented Olivier Taelman, Nyxoah’s (NYXH) CEO. “Our first U.S. patients are experiencing great results; we have a waiting list for additional surgeon training and patients scheduled for implants. Global revenue exceeded EUR 10 million due to the strong U.S. launch and further international geographical expansion. We have established a strong foundation for sustained growth and look forward to expanding Genio adoption in the U.S. throughout 2026.”
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NYXH:
- Nyxoah Launches Genio Therapy in Netherlands and Closes First €22.5 Million Tranche of Convertible Notes
- Nyxoah announces commercial launch of Genio system in the Netherlands
- Nyxoah price target lowered to EUR 5 from EUR 7 at Baird
- Nyxoah Announces Shareholding Changes as Robert Taub Surpasses 10% Threshold
- Nyxoah receives Medicare reimbursement increases for Genio